Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (36)	3/27/1998 9:45:00 PM
From: incomep	Read Replies (1) \| Respond to of 138

In this company's release, Ms Handa mentioned the nucleotide analog for inhibiting the HIV replication? what analog? We already have too nt analog in Biotech. If it is the nt analog, it is almost impossible that HIV genome gets incorporated without the host genome incorporated unless the end T cells specific usage. However, how are they going to use the drug even if it is approved? Anyone know Mr. Hollis-Eden's background? Tingle to short, but the float is too scary--only 1 million/compared with 6.7 million outstanding. This ratio remind me the short experience of YHOO, AOL. They do not have much earning /negative, but they do not have many availabe shares to be tossed around. "Prior to joining Hollis-Eden, Onizuka-Handa was associate director of regulatory affairs at Gilead Sciences, where she participated in the international development of antiviral agents for the treatment of HIV and chronic hepatitis B virus infections. She began her career in 1981 as a biologist at Syntex and held positions for nine years in domestic and international regulatory affairs. During her tenure there, she held several positions, most recently as manager, regulatory resources and intelligence. From 1991-1994, she had responsibilities for both domestic and international regulatory affairs at Genentech. She also held a post at Systemix, Inc., as manager, regulatory affairs. She received a BS degree in animal science from the University of California at Davis. ''I am excited to join a company with such a unique approach to treating infectious diseases and immune system disorders. I will be able to use my recent regulatory experience gained at Gilead Sciences, while working on its nucleotide analog for the treatment of HIV infection, to assist in the development of the lead product candidates at Hollis-Eden.''